Maze Therapeutics, Inc. ( (MAZE) ) has released its Q2 earnings. Here is a breakdown of the information Maze Therapeutics, Inc. presented to its investors.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Maze Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing small molecule precision medicines for kidney and metabolic diseases, leveraging human genetics to target genetically validated pathways.
In its second quarter 2025 financial results, Maze Therapeutics highlighted significant progress in its clinical programs and maintained a robust financial position, with a strong cash reserve expected to support operations into the second half of 2027.
Key developments include the ongoing Phase 1 trial of MZE782 for phenylketonuria (PKU) and chronic kidney disease (CKD), with proof-of-mechanism data anticipated in the third quarter of 2025. Additionally, the Phase 2 HORIZON trial for MZE829, targeting APOL1-mediated kidney disease, continues to enroll patients, with initial data expected in the first quarter of 2026. Financially, the company reported a net loss for the quarter, primarily due to increased R&D and administrative expenses, contrasting with the previous year’s income driven by significant license revenue.
Looking ahead, Maze Therapeutics remains focused on advancing its clinical pipeline, with plans to initiate Phase 2 trials for MZE782 in 2026, and continues to position itself to deliver impactful treatments for patients and value for shareholders.